Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III bought 3,400 shares of the stock in a transaction on Wednesday, November 8th. The stock was purchased at an average price of $19.89 per share, with a total value of $67,626.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Xencor, Inc. (XNCR) traded up $1.07 during trading hours on Monday, reaching $21.03. 146,300 shares of the company’s stock traded hands, compared to its average volume of 215,876. Xencor, Inc. has a 12 month low of $18.55 and a 12 month high of $29.38.
TRADEMARK VIOLATION WARNING: This article was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/11/13/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-purchases-3400-shares.html.
Institutional investors have recently added to or reduced their stakes in the company. Equitec Specialists LLC purchased a new stake in shares of Xencor in the 2nd quarter valued at approximately $116,000. Great West Life Assurance Co. Can increased its stake in Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares during the period. SG Americas Securities LLC increased its stake in Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares during the period. Legal & General Group Plc increased its stake in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in Xencor during the 3rd quarter worth approximately $201,000. 76.70% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on the stock. Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday. Three research analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $30.25.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.